Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel Corporation (NASDAQ:VCEL) is scheduled to report its first-quarter 2023 financial results on May 10, 2023. The company specializes in advanced therapies for sports medicine and serious burn care, offering products such as MACI® and Epicel®. A conference call will take place at 8:30 a.m. (ET) to discuss the results and key business highlights, accessible through the Investor Relations section of its website. Interested participants should register in advance to obtain dial-in details. A replay will be available until May 10, 2024.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, at 12:30 p.m. ET. A webcast of this presentation can be accessed through Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI®, an autologous scaffold for knee cartilage defects, and Epicel®, a permanent skin replacement for severe burns. Vericel also holds exclusive rights to NexoBrid® for burn treatment. For further details, visit the company's official website.
Vericel Corporation (NASDAQ:VCEL) reported robust financial results for Q4 and full-year 2022, with total revenue reaching $52.7 million in Q4, a 31% increase in net income, and total annual revenue of $164.4 million. MACI revenue contributed $132 million for 2022, showing a 24% year-over-year growth in Q4. The company anticipates 2023 total revenue between $180 million and $188 million with MACI revenue estimated at $152 million to $156 million. Notably, Vericel achieved FDA approval for NexoBrid, paving the way for further growth.
Vericel Corporation (NASDAQ: VCEL) is set to report its fourth-quarter 2022 financial results on February 23, 2023. Management will host a conference call and webcast at 8:30 a.m. (ET) to discuss these results along with important business highlights. Interested participants can access the live webcast on Vericel's Investor Relations page and register for the call via the provided link to receive dial-in details. A replay will be available on their website until February 23, 2024. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing notable products like MACI® and Epicel®.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
